Background
==========

Lung cancer is the most frequent cause of cancer mortality \[[@b1-medscimonit-19-95]\] in both men and women \[[@b2-medscimonit-19-95],[@b3-medscimonit-19-95]\]. There are 2 main types of primary lung cancer, which are classified according to cellular population involved: non-small cell lung cancer (NSCLC) and small cell lung cancer. Clinical risk factors for malignancy are age, a history of smoking, hemoptysis, and previous malignancy \[[@b4-medscimonit-19-95]\]. Computerized tomography and positron emission tomography-computed tomography (PET/CT) are crucial for the diagnosis and follow-up of patients affected by lung cancer \[[@b4-medscimonit-19-95]--[@b6-medscimonit-19-95]\]. The aim of this study was to use MDCT and hybrid PET/CT systems to determine whether net enhancement and SUVmax were correlated with tumour size and cytology in patients affected by NSCLC. This disease is an important health problem. Our study could thus be of prognostic significance, and could lead to a more appropriate use of surgical adjuvant treatment and better treatment outcomes.

Material and Methods
====================

Patients
--------

We retrospectively reviewed patients with NSCLC who underwent staging with total body 16-slice multi-detector CT scanning (Brilliance Philips) and with PET/CT (Biograph 16 Siemens Medical Solutions) over a period of 2 years. We studied a selected group of patients affected by N0--N1 and M0 disease and with lesions larger than 3 cm. The final study group consisted of 38 patients (30 men, 8 women, mean age 70 years) with a pulmonary lesion measuring between 3 and 7 cm. These patients were not pre-treated with radio- or chemotherapy. Informed consent was obtained from all 38 patients. The patients' characteristics are reported in [Table 1](#t1-medscimonit-19-95){ref-type="table"}.

Multidetector computed tomography
---------------------------------

All patients underwent multidetector computed tomography (MDCT) (Brilliance 16, Philips Medical Systems, Best, The Netherlands) scanning before and after contrast injection using the following technical parameters: 1.5 mm collimation, 120 Kvp, 250 mA, pitch 0.9, rotation time 0.5 sec, 2 mm reconstruction thickness, 1 mm interval, and standard reconstruction algorithm. Using a biphasic protocol, 120 mL of contrast medium (350 mg of iodine per milliliter) were automatically injected in an antecubital vein: 80 ml at a flow rate of 2 mL/sec, followed by 40 ml at a flow rate of 1.5 mL/sec. A saline bolus of 40 ml at a flow rate of 1.5 ml/sec was injected after contrast media. Scanning was performed from the thoracic inlet to the pelvis 70 seconds after injection.

Net enhancement was calculated by drawing a region of interest (ROI) that covered about half the diameter of the lesion at the equator, but avoided calcified, cavitary and necrotic areas. All measurements in Hounsfield Units (HU) were obtained from the mediastinal window images to minimize partial volume averaging. Density was calculated before (CT pre) and after contrast medium injection, considering average density of the lesion (CT post average). Maximum density (CT-post max) and net enhancement were calculated by subtracting CT-pre values from CT-post average values.

Fine needle aspiration biopsy
-----------------------------

All patients underwent fine needle aspiration biopsy (FNAB), which is a well-established, safe technique for the diagnostic work-up of lung lesions \[[@b7-medscimonit-19-95]\]. The sensitivity of FNAB for the diagnosis of lung cancer ranges from 56% to over 90% and specificity is close to 100% \[[@b7-medscimonit-19-95]\]. In almost all these studies, the overall positive predictive value was nearly 99%. While the false positive rate was generally less than 1%, a negative result is less reliable, with most studies reporting a false negative rate of around 10% \[[@b8-medscimonit-19-95]\].

Computerized tomography and positron emission tomography-computed tomography (PET/CT)
-------------------------------------------------------------------------------------

The injected dose of 18F-FDG varied between 350 and 450 MBq, depending on the patient's weight. In patients with BMI \<25, 350--400 MBq was administered, while patients with those with BMI \>25 received 400--450 MBq. After patients had fasted overnight, we verified that their blood glucose level was below 140 mg before injecting the tracer. During the 60-min uptake phase, the patients were hydrated and instructed to rest comfortably. We used an integrated PET/CT scanner (Biograph 16 Siemens Medical Solutions) consisting of an ultrafast CT scanner with a 16-row multislice detector system, and a PET scanner equipped with a full-ring lutetium oxyorthosilicate system (LSO) with a crystal size of 4×4 mm^2^. Emission data were acquired for 6 to 8 bed positions, typically from the base apex of the skull to the upper thigh, and acquisition time was usually 3 min/bed position, resulting in a total PET scan time of approximately 20--25 min (7 or 8 bed positions), with axial image planes at a 16.2 cm axial field of view per position. The protocol included a low dose (120 KV; 95 mA) non-enhanced CT scan first for attenuation correction, and the 3D-whole-body PET from the base of the skull to the upper thigh. The CT data were used for attenuation correction of PET emission images. PET images were reconstructed by using an iterative algorithm (ordered-subset expectation maximization: 2 iterations, 8 subsets on a 128×128 matrix and with Gaussian post-filtering of 5 mm). The reconstructed PET, CT and fused images were displayed by commercially available software (e-soft/, Siemens Medical Solutions) in axial, coronal and sagittal planes by using a matrix of 128×128 pixels for the PET and 512×512 pixels for the CT and were analyzed by 3 experts in PET. The SUV was also calculated ([Figure 1](#f1-medscimonit-19-95){ref-type="fig"}).

Data description
----------------

The data obtained were examined in relation to the size and cytology of the pulmonary lesion. The data reported (tumour size, CT~pre\ average~, CT~post\ average~, CT~post\ max,~ net enhancement SUVmax, age, cytological results) refer to the 38 patients.

Statistical analysis
--------------------

Correlation coefficients and p-values were computed for each pair of variables. The p-value was computed by transforming the correlation to create a t-statistic with 36 degrees of freedom. The confidence bounds are based on an asymptotic normal distribution of 0.5\*log((1+r)/(1−r)), with an approximate variance equal to 1/(n--3), with n=38. Moreover, to gain more insight, we computed the correlation for each pair of variables, and for all combinations of tumour types. The results were subsequently analyzed for subsets of data with more than 10 samples, and with correlation r\>0.500 and p\<0.05.

Results
=======

As shown in [Table 2](#t2-medscimonit-19-95){ref-type="table"}, there were more male than female patients (n. 30 *vs.* n. 8), which reflects the prevalence of lung carcinoma in the population. Adenocarcinoma ([Figure 2](#f2-medscimonit-19-95){ref-type="fig"}) accounted for approximately one-third of all lung cancers in our study, and is recognized as the most common histotype of lung cancer in many countries \[[@b9-medscimonit-19-95],[@b10-medscimonit-19-95]\].

Overall, we identified a weak, albeit significant, correlation between SUVmax and tumour size (r=0.323, p=0.048). There was no correlation among the pre-contrastographic density of the lesions, net enhancement, average post-contrast density, maximum density and size of lesions ([Table 3](#t3-medscimonit-19-95){ref-type="table"}). The scatter plot of dimension versus SUVmax with the linear regression is depicted in [Figure 3](#f3-medscimonit-19-95){ref-type="fig"}. In particular, we found that the correlation between SUVmax and size was stronger for lesions larger than 31 mm (r=0.4515, p=0.0268). The scatter plot with the regression fit is shown in [Figure 4](#f4-medscimonit-19-95){ref-type="fig"}. Regarding the cytological classification, the correlation between tumour size and SUVmax was slightly stronger in the case of adenocarcinomas ([Figure 5](#f5-medscimonit-19-95){ref-type="fig"}).

Discussion
==========

This study was designed to evaluate whether SUVmax and net enhancement can be correlated with NSCLC in terms of size and histotype in order to assess how these parameters change with tumour size and cytology. We evaluated tumour mass dimension, CT~pre-average~, CT~post-average~, CT~post-max~, net enhancement, SUVmax, age, and cytological data of 38 patients. Recent studies have focused on the relationship between the SUV and biological and molecular factors that influence cancer progression or glucose metabolism \[[@b11-medscimonit-19-95],[@b12-medscimonit-19-95]\]. Malignant cells exhibit increased glucose metabolism and uncontrolled growth: elevated glucose metabolism and high levels of angiogenesis are both associated with increased metastatic potential and poor patient survival \[[@b13-medscimonit-19-95]\]. However, as the tumour increases in size, the cells outgrow their blood supply. The subsequent reduction in the delivery of oxygen renders the tumour hypoxic. Tumours can adapt to hypoxia by increasing the expression of glucose transporters and by utilizing anaerobic glycolysis -- a process mediated by hypoxia-inducible factors \[[@b14-medscimonit-19-95],[@b15-medscimonit-19-95]\]. This mechanism could determine a higher SUVmax in larger malignant lesions.

The relationship between SUV and malignant tumour size has yet to be established. Some authors have identified a correlation between size and SUV \[[@b16-medscimonit-19-95]--[@b18-medscimonit-19-95]\], whereas others did not \[[@b19-medscimonit-19-95],[@b20-medscimonit-19-95]\]. We found a significant correlation between SUVmax and size (r=0.32; p=0.048): this correlation was stronger for lesions larger than 31 mm (r=0.4515; p=0.0268). We also found a correlation between SUVmax and size (r=0.562; p=0.019) in adenocarcinomas. The differences between our results and those of others are probably due to our entry criteria. In fact, we evaluated patients with lesions measuring between 3 and 7 cm and with FDG PET-negative metastasis.

With respect to the correlation between SUVmax and histological type, adenocarcinomas had a slightly lower SUVmax than the other histotypes, but the difference was not significant. The lower SUVmax of adenocarcinomas is consistent with the results of other studies \[[@b1-medscimonit-19-95],[@b2-medscimonit-19-95]\]. Tumour subtype is known to reflect the differential avidity of 18FDG uptake by cancer cells \[[@b21-medscimonit-19-95]\]. Glucose transporters mediate FDG uptake, and the expression of these proteins has been found to correlate with FDG uptake \[[@b22-medscimonit-19-95]\]. Moreover, the expression of glucose transporter type 1 (Glut-1) differed substantially between NSCLC of different histologies \[[@b23-medscimonit-19-95]\]. Adenocarcinomas were reported to express low levels of Glut-1 \[[@b24-medscimonit-19-95]\]. These tumours have a lower 18FDG uptake and a lower SUVmax than squamous cell tumours \[[@b21-medscimonit-19-95]\]. However, although Glut-1 is the major glucose transporter expressed in NSCLC, it is neither the sole nor the rate-limiting determinant of FDG uptake \[[@b25-medscimonit-19-95]\]. FDG uptake is known to be related to hexokinase and glucose-6-phosphatase activities in cancer \[[@b24-medscimonit-19-95],[@b25-medscimonit-19-95]\]. Moreover, at the whole tumour level, FDG depends on such factors as tumour blood flow, intratumoral microvessel density and viable tumour cell number \[[@b2-medscimonit-19-95]\]. Uptake of FDG in the primary site of NSCLC has been correlated with tumour doubling time and proliferation rates \[[@b2-medscimonit-19-95],[@b18-medscimonit-19-95]\]. In fact, the doubling time of squamous cell carcinoma is 92 days versus 168 in the case of adenocarcinoma \[[@b18-medscimonit-19-95]\]. Consequently, there is a link between tumour growth rate and glucose metabolism. This would explain why FDG uptake varies depending on lesion size and histotype, and it would also explain why the correlation between SUVmax and size is stronger for adenocarcinomas than for other histotypes.

We found no correlation between net enhancement and histotype in our 38 patients. According to some studies, the malignant form of pulmonary lesions tends to expand substantially more than the benign form \[[@b26-medscimonit-19-95],[@b27-medscimonit-19-95]\], and perfusion increases proportionally with size \[[@b28-medscimonit-19-95],[@b29-medscimonit-19-95]\]. However, our technique of CT examination, performed to stage the lung masses, does not allow a specific evaluation of net enhancement. In fact, lung masses are usually evaluated with a perfusion or dynamic protocol, which could allow the clinician to correlate net enhancement and histotype \[[@b29-medscimonit-19-95]--[@b31-medscimonit-19-95]\]. However, our subcategories may have been too small to infer any conclusion about this type of parameter.

The results we obtained partially reflect the composition of our group of patients, in which there were fewer women (8/38) and the prevalence of adenocarcinoma was higher than in other studies \[[@b17-medscimonit-19-95],[@b18-medscimonit-19-95]\]. Another problem is the relatively small number of lesions in each group when patients are divided according to histology, particularly in the case of tumours that have a low incidence.

Conclusions
===========

This study shows that tumour size and histological subtype influenced FDG uptake in NSCLC. We found a significant correlation between tumour size and SUV (r=0.32; p=0.048) in patients with lesions measuring between 3 and 7 cm, while we did not find any correlation among lesion size and pre-contrastographic density, net enhancement, average post-contrast density and maximum density. We also demonstrate a significant correlation between clinical stage and SUVmax for adenocarcinomas, but not for squamous cell carcinomas. Our findings should be verified in a larger population, more representative of all histological types and their variants, and taking their different growth patterns and tissue architecture into account.

We are grateful to Jean Ann Gilder (Scientific Communication srl) for revising and editing the text.
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###### 

Cytology, dimension of tumour, CT~pre\ average~, CT~post\ average,~ CT~post\ max,~ net enhancement and SUVmax.

  Cytology                  Dimension mm   CT pre-average   CT post-average   NE   CT post-max   SUVmax
  ------------------------- -------------- ---------------- ----------------- ---- ------------- --------
  Squamous cell carcinoma   50             30               91                61   129           30
  Squamous cell carcinoma   40             39               47                8    86            2.3
  NSCLC                     49             35               76                41   140           14
  NSCLC                     48             56               71                15   100           7.2
  Adenocarcinoma            54             58               98                40   141           9.8
  Squamous cell carcinoma   40             40               70                30   84            11
  NSCLC                     38             35               60                25   128           13
  NSCLC                     30             28               89                61   141           15
  NSCLC                     50             33               59                26   115           15
  Adenocarcinoma            30             24               70                46   98            11
  Large cell                52             13               34                21   74            13
  Adenocarcinoma            30             40               67                27   72            8.8
  Large cell                41             28               55                27   110           13
  Large cell                41             21               41                20   139           19
  Squamous cell carcinoma   64             37               48                11   67            20
  Adenocarcinoma            30             43               69                26   107           8.1
  Adenocarcinoma            30             39               77                38   120           12
  Adenocarcinoma            40             57               102               45   128           11.2
  Adenocarcinoma            50             20               103               83   181           40
  Adenocarcinoma            32             39               56                17   90            10
  Adenocarcinoma            41             36               91                55   117           4
  Adenocarcinoma            41             38               58                20   90            9.2
  Adenocarcinoma            35             38               101               63   152           6.1
  Adenocarcinoma            56             32               65                33   114           34
  Adenocarcinoma            30             65               83                18   116           11
  Adenocarcinoma            30             23               29                6    46            15.4
  Adenocarcinoma            30             22               69                47   106           3.6
  Adenocarcinoma            30             32               87                55   142           2.5
  Adenocarcinoma            54             42               61                19   87            12
  Squamous cell carcinoma   41             20               87                67   118           3.4
  Squamous cell carcinoma   30             35               115               80   151           8
  Squamous cell carcinoma   30             28               33                5    84            4.6
  Squamous cell carcinoma   30             34               86                52   116           38
  Squamous cell carcinoma   60             26               65                39   95            13
  Squamous cell carcinoma   45             31               38                7    68            9.7
  Squamous cell carcinoma   47             42               66                24   125           12
  Squamous cell carcinoma   30             45               110               65   155           13
  Squamous cell carcinoma   31             21               34                13   114           12

###### 

Number of patients, gender, mean age and cytology.

           Patients   Mean age (std. dev.)   Tumour                    Number
  -------- ---------- ---------------------- ------------------------- --------
  Male     30         69 (7.88)              NSCLC                     3
                                             Adenocarcinoma            12
                                             Large cell carcinoma      2
                                             Squamous cell carcinoma   13
                                                                       
  Female   8          63.625 (9.68)          NSCLC                     2
                                             Adenocarcinoma            5
                                             Large cell carcinoma      1
                                                                       
  Total    38         67.87 (8.32)           NSCLC                     5
                                             Adenocarcinoma            17
                                             Large cell carcinoma      3
                                             Squamous cell carcinoma   13

###### 

Correlation among pre-contrastographic density of the lesions, net enhancement, average post-contrast density, maximum density and dimension of lesions.

  Correlation       Dimension   CT pre average   CT post average   Net enhancement   CT post max   SUVmax
  ----------------- ----------- ---------------- ----------------- ----------------- ------------- --------
  Dimension         1.000       −0.007           −0.121            −0.126            −0.084        0.323
  CT pre average    −0.007      1.000            0.384             −0.123            0.093         −0.204
  CT post average   −0.121      0.384            1.000             0.869             0.751         0.107
  Net enhancement   −0.126      −0.123           0.869             1.000             0.757         0.225
  CT post max       −0.084      0.093            0.751             0.757             1.000         0.238
  SUVmax            0.323       −0.204           0.107             0.225             0.238         1.000
  p-value           Dimension   CT pre average   CT post average   Net enhancement   CT post max   SUVmax
  Dimension         1.000       0.968            0.471             0.451             0.615         0.048
  CT pre average    0.968       1.000            0.018             0.461             0.577         0.219
  CT post average   0.471       0.018            1.000             0.000             0.000         0.522
  Net enhancement   0.451       0.461            0.000             1.000             0.000         0.175
  CT post max       0.615       0.577            0.000             0.000             1.000         0.151
  SUVmax            0.048       0.219            0.522             0.175             0.151         1.000
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